Phase I/II, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Pembrolizumab in Patients with Solid Tumors, including Pancreatic Cancer (GLIMMER-01)
The purpose of this phase I/II trial is to evaluate the safety and tolerability of E-602 as a monotherapy and E-602 in combination with pembrolizumab in patients with solid tumors, including pancreatic cancer.
Study ID: PAL-E602-001
Trial Phase: Phase I/II
Trial Sponsor: Palleon Pharmaceuticals, Inc.
Therapies Used in This Trial: Pembrolizumab, E-602